Q-omics provides the consensus-scored ABHD14A profile across patient tissues and cancer cell-line models. ABHD14A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ABHD14A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ABHD14A RNA expression shows 17,220 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where ABHD14A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD14A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD14A survival associations across molecular data types. ABHD14A RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD14A RNA expression–survival associations across cancer types. High ABHD14A expression shows unfavorable associations in KIRC, UCS and ACC, but favorable associations in KIRP, BRCA and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ABHD14A RNA expression.
This table summarizes ABHD14A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ABHD14A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD14A shows lower tumor expression in KIRC, KICH, KIRP, LUSC and BRCA and higher tumor expression in LIHC. The KIRC box plot shows higher ABHD14A RNA expression in normal versus tumor tissue (log2 FC = −0.966, t-test p < 0.001).
This table shows molecular features associated with ABHD14A in patient tissues and cancer cell lines. In patient samples, ABHD14A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD14A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
